18 0 2 0 2 B-lower_bound
years 3 8 3 8 I-lower_bound
or 9 11 9 11 O
older 12 17 12 17 O

AML 0 3 18 21 B-cancer
as 4 6 22 24 O
defined 7 14 25 32 O
by 15 17 33 35 O
the 18 21 36 39 O
WHO 22 25 40 43 O
Classification 26 40 44 58 O
either 41 47 59 65 O
persisting 48 58 66 76 O
/ 58 59 76 77 O
refractory 59 69 77 87 O
after 70 75 88 93 O
at 76 78 94 96 O
least 79 84 97 102 O
2 85 86 103 104 B-lower_bound
primary 87 94 105 112 O
induction 95 104 113 122 O
courses 105 112 123 130 O
( 113 114 131 132 O
ie 114 116 132 134 O
, 116 117 134 135 O
no 118 120 136 138 O
response 121 129 139 147 O
after 130 135 148 153 O
at 136 138 154 156 O
least 139 144 157 162 O
2 145 146 163 164 O
prior 147 152 165 170 B-treatment
chemotherapy 153 165 171 183 I-treatment
cycles 166 172 184 190 O
) 172 173 190 191 O
or 174 176 192 194 O
recurring 177 186 195 204 O
after 187 192 205 210 O
having 193 199 211 217 O
achieved 200 208 218 226 O
an 209 211 227 229 O
initial 212 219 230 237 O
response 220 228 238 246 O
to 229 231 247 249 O
chemotherapy 232 244 250 262 O

AML 0 3 263 266 B-cancer
as 4 6 267 269 O
defined 7 14 270 277 O
by 15 17 278 280 O
the 18 21 281 284 O
WHO 22 25 285 288 O
Classification 26 40 289 303 O
persisting 41 51 304 314 O
or 52 54 315 317 O
recurring 55 64 318 327 O
following 65 74 328 337 O
one 75 78 338 341 B-lower_bound
or 79 81 342 344 O
more 82 86 345 349 O
treatment 87 96 350 359 B-treatment
courses 97 104 360 367 O

AML 0 3 368 371 B-cancer
secondary 4 13 372 381 I-cancer
to 14 16 382 384 O
prior 17 22 385 390 O
myelodysplastic 23 38 391 406 B-cancer
syndrome 39 47 407 415 I-cancer

Active 0 6 416 422 O
extramedullary 7 21 423 437 O
AML 22 25 438 441 B-cancer
in 26 28 442 444 O
testes 29 35 445 451 O
or 36 38 452 454 O
central 39 46 455 462 O
nervous 47 54 463 470 O
system 55 61 471 477 O
( 62 63 478 479 O
CNS 63 66 479 482 O
) 66 67 482 483 O

All 0 3 484 487 O
herbal 4 10 488 494 B-treatment
medicines 11 20 495 504 I-treatment
( 21 22 505 506 O
eg 22 24 506 508 O
, 24 25 508 509 O
St. 26 29 510 513 B-treatment
John 30 34 514 518 I-treatment
's 34 36 518 520 I-treatment
wort 37 41 521 525 I-treatment
) 41 42 525 526 O
, 42 43 526 527 O
vitamins 44 52 528 536 O
, 52 53 536 537 O
and 54 57 538 541 O
supplements 58 69 542 553 O
consumed 70 78 554 562 O
by 79 81 563 565 O
the 82 85 566 569 O
subject 86 93 570 577 O
within 94 100 578 584 O
the 101 104 585 588 O
30 105 107 589 591 B-upper_bound
days 108 112 592 596 I-upper_bound
prior 113 118 597 602 I-upper_bound
to 119 121 603 605 O
receiving 122 131 606 615 O
the 132 135 616 619 O
first 136 141 620 625 O
dose 142 146 626 630 O
of 147 149 631 633 O
AMG 150 153 634 637 B-treatment
330 154 157 638 641 I-treatment

Allogeneic 0 10 642 652 B-treatment
HSCT 11 15 653 657 I-treatment
within 16 22 658 664 O
three 23 28 665 670 B-upper_bound
months 29 35 671 677 I-upper_bound
prior 36 41 678 683 I-upper_bound
to 42 44 684 686 O
start 45 50 687 692 O
of 51 53 693 695 O
AMG 54 57 696 699 B-treatment
330 58 61 700 703 I-treatment
treatment 62 71 704 713 I-treatment

Antitumor 0 9 714 723 B-treatment
therapy 10 17 724 731 I-treatment
( 18 19 732 733 O
chemotherapy 19 31 733 745 B-treatment
, 31 32 745 746 O
antibody 33 41 747 755 B-treatment
therapy 42 49 756 763 I-treatment
, 49 50 763 764 O
molecular 51 60 765 774 B-treatment
- 60 61 774 775 I-treatment
targeted 61 69 775 783 I-treatment
therapy 70 77 784 791 I-treatment
, 77 78 791 792 O
retinoid 79 87 793 801 B-treatment
therapy 88 95 802 809 I-treatment
, 95 96 809 810 O
or 97 99 811 813 O
investigational 100 115 814 829 B-treatment
agent 116 121 830 835 I-treatment
) 121 122 835 836 O
within 123 129 837 843 O
14 130 132 844 846 B-upper_bound
days 133 137 847 851 I-upper_bound
or 138 140 852 854 O
5 141 142 855 856 B-upper_bound
half 143 147 857 861 O
- 147 148 861 862 O
lives 148 153 862 867 O
of 154 156 868 870 O
day 157 160 871 874 O
1 161 162 875 876 O

Autologous 0 10 877 887 B-treatment
HSCT 11 15 888 892 I-treatment
within 16 22 893 899 O
six 23 26 900 903 B-upper_bound
weeks 27 32 904 909 I-upper_bound
prior 33 38 910 915 I-upper_bound
to 39 41 916 918 O
start 42 47 919 924 O
of 48 50 925 927 O
AMG 51 54 928 931 B-treatment
330 55 58 932 935 I-treatment
treatment 59 68 936 945 I-treatment

ECOG 0 4 946 950 B-clinical_variable
Performance 5 16 951 962 I-clinical_variable
Status 17 23 963 969 I-clinical_variable
of 24 26 970 972 O
≤ 27 28 973 974 O
2 29 30 975 976 B-upper_bound

History 0 7 977 984 O
of 8 10 985 987 O
arterial 11 19 988 996 B-chronic_disease
thrombosis 20 30 997 1007 I-chronic_disease
( 31 32 1008 1009 O
eg 32 34 1009 1011 O
, 34 35 1011 1012 O
stroke 36 42 1013 1019 B-chronic_disease
or 43 45 1020 1022 O
transient 46 55 1023 1032 B-chronic_disease
ischemic 56 64 1033 1041 I-chronic_disease
attack 65 71 1042 1048 I-chronic_disease
) 71 72 1048 1049 O
in 73 75 1050 1052 O
the 76 79 1053 1056 O
past 80 84 1057 1061 B-upper_bound
3 85 86 1062 1063 I-upper_bound
months 87 93 1064 1070 I-upper_bound
Infection 94 103 1071 1080 B-chronic_disease
requiring 104 113 1081 1090 O
intravenous 114 125 1091 1102 B-treatment
antibiotics 126 137 1103 1114 I-treatment
within 138 144 1115 1121 O
1 145 146 1122 1123 B-upper_bound
week 147 151 1124 1128 I-upper_bound
of 152 154 1129 1131 O
study 155 160 1132 1137 O
enrollment 161 171 1138 1148 O
( 172 173 1149 1150 O
day 173 176 1150 1153 O
1 177 178 1154 1155 O
) 178 179 1155 1156 O

Ingestion 0 9 1157 1166 O
of 10 12 1167 1169 O
any 13 16 1170 1173 O
food 17 21 1174 1178 O
or 22 24 1179 1181 O
drink 25 30 1182 1187 O
containing 31 41 1188 1198 O
grapefruit 42 52 1199 1209 O
or 53 55 1210 1212 O
Seville 56 63 1213 1220 O
oranges 64 71 1221 1228 O
, 71 72 1228 1229 O
or 73 75 1230 1232 O
St. 76 79 1233 1236 O
John´s 80 86 1237 1243 O
wort 87 91 1244 1248 O
, 91 92 1248 1249 O
within 93 99 1250 1256 O
7 100 101 1257 1258 B-upper_bound
days 102 106 1259 1263 I-upper_bound
prior 107 112 1264 1269 I-upper_bound
to 113 115 1270 1272 O
receiving 116 125 1273 1282 O
the 126 129 1283 1286 O
first 130 135 1287 1292 O
dose 136 140 1293 1297 O
of 141 143 1298 1300 O
AMG 144 147 1301 1304 B-treatment
330 148 151 1305 1308 I-treatment

Known 0 5 1309 1314 O
hypersensitivity 6 22 1315 1331 O
to 23 25 1332 1334 O
immunoglobulins 26 41 1335 1350 B-allergy_name
or 42 44 1351 1353 O
to 45 47 1354 1356 O
any 48 51 1357 1360 O
other 52 57 1361 1366 O
component 58 67 1367 1376 B-allergy_name
of 68 70 1377 1379 I-allergy_name
the 71 74 1380 1383 I-allergy_name
IP 75 77 1384 1386 I-allergy_name
formulation 78 89 1387 1398 I-allergy_name

Known 0 5 1399 1404 O
positiv 6 13 1405 1412 O
test 14 18 1413 1417 O
for 19 22 1418 1421 O
HIV 23 26 1422 1425 B-chronic_disease

Major 0 5 1426 1431 B-treatment
surgery 6 13 1432 1439 I-treatment
within 14 20 1440 1446 O
28 21 23 1447 1449 B-upper_bound
days 24 28 1450 1454 I-upper_bound
of 29 31 1455 1457 O
study 32 37 1458 1463 O
day 38 41 1464 1467 O
1 42 43 1468 1469 O

More 0 4 1470 1474 O
than 5 9 1475 1479 O
5 10 11 1480 1481 B-lower_bound
% 11 12 1481 1482 I-lower_bound
blasts 13 19 1483 1489 I-lower_bound
in 20 22 1490 1492 O
bone 23 27 1493 1497 O
marrow 28 34 1498 1504 O

Positive 0 8 1505 1513 O
for 9 12 1514 1517 O
Hepatitis 13 22 1518 1527 B-chronic_disease
B 23 24 1528 1529 I-chronic_disease

Positive 0 8 1530 1538 O
for 9 12 1539 1542 O
Hepatitis 13 22 1543 1552 B-chronic_disease
C 23 24 1553 1554 I-chronic_disease
or 25 27 1555 1557 O
chronic 28 35 1558 1565 B-chronic_disease
Hepatitis 36 45 1566 1575 I-chronic_disease
C 46 47 1576 1577 I-chronic_disease

Prior 0 5 1578 1583 B-treatment
participation 6 19 1584 1597 I-treatment
in 20 22 1598 1600 I-treatment
an 23 25 1601 1603 I-treatment
investigational 26 41 1604 1619 I-treatment
study 42 47 1620 1625 I-treatment
within 48 54 1626 1632 O
21 55 57 1633 1635 B-upper_bound
days 58 62 1636 1640 I-upper_bound
of 63 65 1641 1643 O
study 66 71 1644 1649 O
day 72 75 1650 1653 O
1 76 77 1654 1655 O

Prior 0 5 1656 1661 B-treatment
treatment 6 15 1662 1671 I-treatment
with 16 20 1672 1676 I-treatment
a 21 22 1677 1678 I-treatment
chimeric 23 31 1679 1687 I-treatment
antigen 32 39 1688 1695 I-treatment
receptor 40 48 1696 1704 I-treatment
T 49 50 1705 1706 I-treatment
cell 51 55 1707 1711 I-treatment
( 56 57 1712 1713 I-treatment
CAR 57 60 1713 1716 I-treatment
- 60 61 1716 1717 I-treatment
T 61 62 1717 1718 I-treatment
) 62 63 1718 1719 I-treatment
infusion 64 72 1720 1728 I-treatment
for 73 76 1729 1732 O
the 77 80 1733 1736 O
treatment 81 90 1737 1746 O
of 91 93 1747 1749 O
AML 94 97 1750 1753 B-cancer
( 98 99 1754 1755 O
CD33 99 103 1755 1759 O
or 104 106 1760 1762 O
other 107 112 1763 1768 O
target 113 119 1769 1775 O
) 119 120 1775 1776 O

Treatment 0 9 1777 1786 B-treatment
with 10 14 1787 1791 O
systemic 15 23 1792 1800 O
immune 24 30 1801 1807 B-treatment
modulators 31 41 1808 1818 I-treatment
2 42 43 1819 1820 B-upper_bound
weeks 44 49 1821 1826 I-upper_bound
before 50 56 1827 1833 O
enrollment 57 67 1834 1844 O
( 68 69 1845 1846 O
day 69 72 1846 1849 O
1 73 74 1850 1851 O
) 74 75 1851 1852 O

Unresolved 0 10 1853 1863 O
toxicities 11 21 1864 1874 O
from 22 26 1875 1879 O
prior 27 32 1880 1885 B-treatment
antitumor 33 42 1886 1895 I-treatment
therapy 43 50 1896 1903 I-treatment
, 50 51 1903 1904 O
defined 52 59 1905 1912 O
as 60 62 1913 1915 O
not 63 66 1916 1919 O
having 67 73 1920 1926 O
resolved 74 82 1927 1935 O
to 83 85 1936 1938 O
CTCAE 86 91 1939 1944 O
, 91 92 1944 1945 O
version 93 100 1946 1953 O
4.0 101 104 1954 1957 O
grade 105 110 1958 1963 O
1 111 112 1964 1965 O

White 0 5 1966 1971 B-clinical_variable
blood 6 11 1972 1977 I-clinical_variable
cells 12 17 1978 1983 I-clinical_variable
( 18 19 1984 1985 I-clinical_variable
WBC 19 22 1985 1988 I-clinical_variable
) 22 23 1988 1989 I-clinical_variable
> 24 25 1990 1991 O
15,000 26 32 1992 1998 B-lower_bound
cells 33 38 1999 2004 I-lower_bound
/ 38 39 2004 2005 I-lower_bound
mcL 39 42 2005 2008 I-lower_bound
at 43 45 2009 2011 O
screening 46 55 2012 2021 O

Women 0 5 2022 2027 B-gender
planning 6 14 2028 2036 B-pregnancy
to 15 17 2037 2039 I-pregnancy
become 18 24 2040 2046 I-pregnancy
pregnant 25 33 2047 2055 I-pregnancy
while 34 39 2056 2061 O
on 40 42 2062 2064 O
study 43 48 2065 2070 O
through 49 56 2071 2078 O
1 57 58 2079 2080 B-upper_bound
week 59 63 2081 2085 I-upper_bound
after 64 69 2086 2091 I-upper_bound
receiving 70 79 2092 2101 O
the 80 83 2102 2105 O
last 84 88 2106 2110 O
dose 89 93 2111 2115 O
of 94 96 2116 2118 O
study 97 102 2119 2124 B-treatment
drug 103 107 2125 2129 I-treatment

Women 0 5 2130 2135 B-gender
who 6 9 2136 2139 O
are 10 13 2140 2143 O
lactating 14 23 2144 2153 O
/ 23 24 2153 2154 O
breastfeeding 24 37 2154 2167 O
or 38 40 2168 2170 O
who 41 44 2171 2174 O
plan 45 49 2175 2179 O
to 50 52 2180 2182 O
breastfeed 53 63 2183 2193 O
while 64 69 2194 2199 O
on 70 72 2200 2202 O
sudy 73 77 2203 2207 O
through 78 85 2208 2215 O
1 86 87 2216 2217 B-upper_bound
week 88 92 2218 2222 I-upper_bound
after 93 98 2223 2228 I-upper_bound
receiving 99 108 2229 2238 O
the 109 112 2239 2242 O
last 113 117 2243 2247 O
dose 118 122 2248 2252 O
of 123 125 2253 2255 O
study 126 131 2256 2261 B-treatment
drug 132 136 2262 2266 I-treatment

Women 0 5 2267 2272 B-gender
with 6 10 2273 2277 O
a 11 12 2278 2279 O
positive 13 21 2280 2288 B-pregnancy
pregnancy 22 31 2289 2298 I-pregnancy
test 32 36 2299 2303 O

biopsy 0 6 2304 2310 B-treatment
and 7 10 2311 2314 O
long 11 15 2315 2319 B-treatment
line 16 20 2320 2324 I-treatment
insertion 21 30 2325 2334 I-treatment

promyelocytic 0 13 2335 2348 B-cancer
leukemia 14 22 2349 2357 I-cancer
( 23 24 2358 2359 I-cancer
APML 24 28 2359 2363 I-cancer
) 28 29 2363 2364 I-cancer

